Improvement of cardiovascular remodelling by chymase inhibitor

Clinical and Experimental Pharmacology & Physiology
S Takai, D Jin

Abstract

Chymase has been identified as an angiotensin II-forming enzyme found in cardiovascular tissues. Angiotensin II is involved not only in the regulation of blood pressure, but also in the progression of cardiovascular remodelling. Interestingly, chymase inhibitors prevent cardiovascular remodelling without lowering blood pressure. The reason why chymase inhibitors do not affect blood pressure may depend on the localization of chymase in vivo. In normal tissues, chymase is stored in mast cell granules and has no enzymatic function; whereas, in damaged tissues, chymase exhibits enzymatic activity immediately following its release from the granules. Chymase also activates transforming growth factor-β and matrix metalloproteinase-9, both of which are involved in cardiovascular remodelling, and their enzymatic functions are also observed only in damaged tissues. In animal models of hypertension, diabetes and hypercholesterolaemia, chymase inhibitors improve cardiovascular remodelling without a general circulatory effect, including blood pressure. Thus, it is proposed that chymase is a potentially important target for preventing cardiovascular diseases.

References

Sep 1, 1991·Clinical and Experimental Pharmacology & Physiology·H OkunishiM Miyazaki
Feb 1, 1991·Journal of Molecular and Cellular Cardiology·R G SchoemakerJ F Smits
Oct 2, 1990·The American Journal of Cardiology·G S Francis
Jul 14, 1988·The New England Journal of Medicine·M A PfefferE Braunwald
Apr 1, 1987·Archives of Biochemistry and Biophysics·M B De YoungA Scarpa
Nov 1, 1984·The Journal of Investigative Dermatology·B U WintroubL B Schwartz
Jun 1, 1993·Japanese Journal of Pharmacology·H OkunishiM Miyazaki
Nov 14, 1997·Clinica Chimica Acta; International Journal of Clinical Chemistry·S TakaiM Miyazaki
Jan 24, 1998·Biochemical and Biophysical Research Communications·D YamamotoM Miyazaki
Sep 19, 1998·Journal of the American College of Cardiology·M KaartinenP T Kovanen
May 13, 1999·The Journal of Endocrinology·M TahmasebiG P Vinson
Jul 19, 2000·Biochimica Et Biophysica Acta·G H CaugheyP J Wolters
Jul 19, 2001·Japanese Journal of Pharmacology·D JinM Miyazaki
Jun 6, 2002·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Masayuki FukudaToshio Ogihara
Aug 15, 2002·Cardiovascular Research·Yoshinari UeharaKeijiro Saku
Aug 27, 2002·Journal of Hypertension·Lars H LindholmUNKNOWN LIFE study group
Feb 18, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Markus J LeskinenPetri T Kovanen
Feb 18, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Beril TomA H Jan Danser
Mar 21, 2003·Biochemical and Biophysical Research Communications·Kayo SaitoYoshiaki Fukuda
May 27, 2003·Diabetes·Henriette R OliveiraAngelo R Carpinelli
Nov 14, 2003·Cardiovascular Research·Denan JinMizuo Miyazaki
Dec 4, 2003·The International Journal of Biochemistry & Cell Biology·Siu Wai TsangPo Sing Leung
Jan 20, 2004·The Journal of Pharmacology and Experimental Therapeutics·Denan JinMizuo Miyazaki
Aug 18, 2004·Clinica Chimica Acta; International Journal of Clinical Chemistry·Kenichi OkumuraMizuo Miyazaki
Sep 15, 2005·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Kazuyoshi KirimuraMizuo Miyazaki
Oct 19, 2006·Biochemical and Biophysical Research Communications·Sayaka NagataKazuo Kitamura
Oct 30, 2007·Clinica Chimica Acta; International Journal of Clinical Chemistry·Keiichi FurubayashiHitoshi Fukumoto
Apr 29, 2008·Pharmacology & Therapeutics·Daiju Fukuda, Masataka Sata

❮ Previous
Next ❯

Citations

Apr 10, 2016·Journal of Molecular and Cellular Cardiology·Ashley L EadieKeith R Brunt
Jun 3, 2017·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Carlos M Ferrario, Adam E Mullick
May 26, 2017·Expert Opinion on Drug Discovery·Maria Tamargo, Juan Tamargo
Nov 7, 2016·American Journal of Physiology. Heart and Circulatory Physiology·Ghezal FrooghDong Sun
Jun 8, 2018·Clinical Pharmacology in Drug Development·Friederike KanefendtChristiane Otto
May 14, 2016·Circulation Research·Irene AlfarasRafael de Cabo
Feb 4, 2019·Molecular and Cellular Biochemistry·Hao WangLeanne Groban
Jan 1, 2020·BMC Cardiovascular Disorders·Dongchen ZhouXudong Xie
Oct 18, 2020·International Journal of Molecular Sciences·Shinji Takai, Denan Jin
Feb 10, 2020·The American Journal of Pathology·Zaid AbassiSamuel N Heyman
May 25, 2021·Frontiers in Cardiovascular Medicine·Michele CorrealeNatale Daniele Brunetti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

Related Papers

Journal of the Renin-angiotensin-aldosterone System : JRAAS
M Miyazaki, S Takai
Japanese Journal of Pharmacology
S Takai, Mizuo Miyazaki
Drug News & Perspectives
S Takai, Mizuo Miyazaki
© 2022 Meta ULC. All rights reserved